kreiley

For life sciences executives, intellectual property risk is typically framed around patents, exclusivity periods, and litigation exposure. Yet an increasing risk to enterprise value sits outside traditional IP modeling: the disclosure of commercially sensitive information through expanding regulatory transparency frameworks.

As global regulators increase public access to clinical and regulatory submissions, disclosure is no longer a […]

As coaches and managers, we spend a lot of time and energy making sure our employees are okay. We worry about how to give feedback in a way that will build them up and give them confidence to grow. We worry about how to talk and listen effectively. We stay up at night strategizing how […]

In today’s highly regulated, data-driven, and competitive life sciences environment, pharmaceutical, biotech, and medical device companies face increasing pressure to operate faster, more efficiently, and more intelligently. From commercial operations and regulatory compliance to supply chain management and financial planning, the number of business-critical processes that must work in harmony has never been greater.

Traditionally, many […]

Introduction

Fair Market Value (FMV) remains a central focus within the life sciences industry, as underscored at the recent Pharmaceutical and Medical Device Ethics and Compliance Congress. As the regulatory environment continues to evolve, companies are under increasing scrutiny regarding the appropriateness of compensation paid to healthcare professionals (HCPs). Corporate integrity agreements repeatedly highlight deficiencies in […]